Arbutus Biopharma Corp (FRA:I9DN)
€ 3.448 -0.098 (-2.76%) Market Cap: 687.51 Mil Enterprise Value: 558.40 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 50/100

Arbutus Biopharma Corp at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 01:00PM GMT
Release Date Price: €2.3
Roy Buchanan
JMP Securities - Analyst

Happy to kick it off with Arbutus Biopharma here today. They have the whole team with us here. Bill Collier is President and CEO; Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. So thanks for joining us, everyone.

Bill Collier
Arbutus Biopharma Corporation - President, CEO, & Director

Thank you.

Dave Hastings
Arbutus Biopharma Corporation - CFO

Thanks, Roy.

Mike Sofia
Arbutus Biopharma Corporation - Chief Scientific Officer

Thanks.

Roy Buchanan
JMP Securities - Analyst

Glad you guys could be here. So pretty exciting year coming up. You guys are developing, obviously, treatments for chronic hepatitis B, trying to get to a functional cure, also coronavirus therapeutics.

Questions & Answers

Roy Buchanan
JMP Securities - Analyst

So let's start off with the chronic hepatitis B. You've got a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot